LUCY
Innovative Eyewear, Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$0.93
+2.73%Year over year
Reported trailing growth
- Revenue
- +72.5%
- EBITDA
- -0.2%
- EBIT
- -6.1%
- EPS
- +58.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +61.2%
- EBITDA
- +61.2%
- EPS
- +64.4%
Three-year CAGR
- Revenue
- +59.2%
- EBITDA
- +2.1%
- EBIT
- -7.2%
- Net income
- +2.3%
- EPS
- +63.4%
- Free cash flow
- -7.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026